AU2018309026A1 - Wnt compositions and methods of process from serum-free culturing conditions - Google Patents

Wnt compositions and methods of process from serum-free culturing conditions Download PDF

Info

Publication number
AU2018309026A1
AU2018309026A1 AU2018309026A AU2018309026A AU2018309026A1 AU 2018309026 A1 AU2018309026 A1 AU 2018309026A1 AU 2018309026 A AU2018309026 A AU 2018309026A AU 2018309026 A AU2018309026 A AU 2018309026A AU 2018309026 A1 AU2018309026 A1 AU 2018309026A1
Authority
AU
Australia
Prior art keywords
wnt
polypeptide
composition
wnt3a
cases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018309026A
Other languages
English (en)
Inventor
Stefanie GASTER
Jill Helms
Bo Liu
Ping Yuan
Ying Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ankasa Regenerative Therapeutics Inc
Original Assignee
Ankasa Regenerative Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ankasa Regenerative Therapeutics Inc filed Critical Ankasa Regenerative Therapeutics Inc
Publication of AU2018309026A1 publication Critical patent/AU2018309026A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018309026A 2017-08-01 2018-08-01 Wnt compositions and methods of process from serum-free culturing conditions Abandoned AU2018309026A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762539960P 2017-08-01 2017-08-01
US62/539,960 2017-08-01
US201862630448P 2018-02-14 2018-02-14
US62/630,448 2018-02-14
PCT/US2018/044886 WO2019028186A1 (en) 2017-08-01 2018-08-01 WNT COMPOSITIONS AND METHODS OF TREATMENT FROM SERUM-FREE CULTURE CONDITIONS

Publications (1)

Publication Number Publication Date
AU2018309026A1 true AU2018309026A1 (en) 2020-03-12

Family

ID=65234165

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018309026A Abandoned AU2018309026A1 (en) 2017-08-01 2018-08-01 Wnt compositions and methods of process from serum-free culturing conditions

Country Status (8)

Country Link
US (1) US20200399588A1 (https=)
EP (1) EP3661475A4 (https=)
JP (2) JP2020529845A (https=)
CN (1) CN111182880B (https=)
AU (1) AU2018309026A1 (https=)
CA (1) CA3071638A1 (https=)
GB (2) GB2581882B (https=)
WO (1) WO2019028186A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019121846A1 (en) * 2017-12-19 2019-06-27 CSL Behring Lengnau AG Protein purification and virus inactivation with alkyl glycosides
WO2021213623A1 (en) * 2020-04-20 2021-10-28 Pharmact Holding Ag A modified bacterial hyaluronidase polypeptide, production process, pharmaceutical compositions and their uses
CN116359367B (zh) * 2022-12-27 2023-08-25 绍兴市食品药品检验研究院 一种同位素内标高效液相色谱串联质谱法检测食品中γ-氨基丁酸的方法
US20260023050A1 (en) * 2024-07-22 2026-01-22 Waters Technologies Corporation Methods for analyzing lipid nanoparticles and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0707472T3 (da) * 1993-07-08 2001-04-17 Liposome Co Inc Fremgangsmåde til regulering af størrelsen af liposomer
US6610316B2 (en) * 1997-05-30 2003-08-26 Shanbrom Technologies, Llc Disinfection by particle-bound and insolubilized detergents
WO2006036175A2 (en) * 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Wnt proteins and detection and treatment of cancer
US20070072238A1 (en) * 2005-09-26 2007-03-29 Wyeth Wnt-frizzled chimera
US8431532B2 (en) * 2010-06-28 2013-04-30 Five Prime Therepeutics, Inc. FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same
AU2012308476B2 (en) * 2011-09-16 2016-04-14 Fate Therapeutics, Inc. Wnt compositions and therapeutic uses of such compositions
WO2014066328A1 (en) * 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
WO2015051122A2 (en) * 2013-10-02 2015-04-09 The Board Of Trustees Of The Leland Stanford Junior University Wnt compositions and methods for purification
CN108601818A (zh) * 2016-01-28 2018-09-28 小利兰·斯坦福大学托管委员会 Wnt组合物及其无血清合成方法

Also Published As

Publication number Publication date
GB202001567D0 (en) 2020-03-18
JP2024120178A (ja) 2024-09-04
GB2610090A (en) 2023-02-22
EP3661475A1 (en) 2020-06-10
CN111182880A (zh) 2020-05-19
GB2581882A (en) 2020-09-02
GB202216232D0 (en) 2022-12-14
EP3661475A4 (en) 2021-06-02
CA3071638A1 (en) 2019-02-07
GB2581882B (en) 2023-03-29
JP2020529845A (ja) 2020-10-15
WO2019028186A1 (en) 2019-02-07
GB2610090B (en) 2023-05-17
US20200399588A1 (en) 2020-12-24
CN111182880B (zh) 2024-01-09

Similar Documents

Publication Publication Date Title
US20200399588A1 (en) Wnt compositions and methods of process from serum-free culturing conditions
CN103732628B (zh) 多价杂多聚体骨架设计和构建体
JP6688237B2 (ja) タンパク質発現増強ポリペプチド
US20220325238A1 (en) Wnt compositions and methods for serum-free synthesis
JP2005521383A (ja) 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド
AU2019208196B2 (en) Wnt compositions and methods for purification
JP2005506061A (ja) 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド
EP3892632A1 (en) Modified product of fc domain of antibody
WO2018058088A1 (en) Cell-associated secretion-enhancing fusion proteins
AU2020243073B2 (en) Recombinant CCN domain proteins and fusion proteins
JP2009544325A (ja) Ｂｍｐ−７変異体組成物、方法および使用
RU2825102C2 (ru) Рекомбинантные белки с доменами ccn и слитые белки

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application